Information Provided By:
Fly News Breaks for January 27, 2020
Jan 27, 2020 | 16:13 EDT
BMO Capital analyst George Farmer initiated coverage of Seattle Genetics with an Outperform rating and $139 price target. Adcetris remains a mainstay for treatment of Hodgkin's lymphoma, label expansions can add another leg to growth for the drug, and the sales potential of pipeline assets Padcev for urothelial cancer and tucatinib in metastatic breast cancer are not fully reflected in the current share price, Farmer tells investors.
News For SGEN From the Last 2 Days
There are no results for your query SGEN